最初的布雷德伍德诉贝塞拉裁决对结直肠癌结局的影响:一项建模研究
Rosita Van Den Puttelaar1, Kewei Sylvia Shi2, Robert Smith3
1Department of Public Health, Erasmus University Medical Center, 3015GD Rotterdam, The Netherlands.
Journal of the National Cancer Institute
|October 3, 2024
概括
恢复预防服务的成本共享可能会增加结肠直肠癌 (CRC) 查成本和发病率. 查参与率的显著下降可能导致CRC发病率和死亡率上升.
科学领域:
- 卫生政策 卫生政策
- 预防医学 预防医学
- 癌症流行病学癌症流行病学
背景情况:
- 负担得起的医疗保健法案 (ACA) 消除了美国预防服务工作组 (USPSTF) 推的服务的患者成本共享.
- 法院的一项裁决 (布雷德伍德管理公司诉贝塞拉) 威胁要恢复USPSTF推服务的成本共享,影响超过1.5亿个人.
- 这一裁决特别针对45-49岁的结肠直肠癌 (CRC) 查和结肠镜检查期间的多片切除.
研究的目的:
- 模拟恢复成本共享对CRC结果的潜在影响.
- 评估减少查参与对CRC发病率和死亡率的影响.
- 分析查率和诊断变化的经济影响.
主要方法:
- 使用MISCAN-Colon模型进行模拟.
- 早期开始的CRC的综合趋势.
- 假设查参与率下降.
主要成果:
- 查参与率下降8个百分点可能导致CRC发病率增加5.1%,CRC死亡率增加9.1%.
- 由于患者成本共享的增加,预计医疗保健成本略有降低.
- 查参与率较大减少与发病率增加和诊断延迟有关,可能会增加总体成本.
结论:
- 恢复预防性服务的成本共享,特别是CRC查,可能对公共卫生结果产生重大不利影响.
- 由于成本障碍,查参与率下降可能会加剧结直肠癌的负担.
- 关于预防性护理成本共享的政策决策对癌症发病率,死亡率和医疗保健经济有重大影响.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
898
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
01:21Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870